(0.05%) 5 472.02 points
(0.05%) 39 133 points
(0.37%) 17 783 points
(-0.02%) $80.81
(-3.66%) $2.66
(-0.76%) $2 313.20
(0.23%) $28.94
(3.61%) $1 022.00
(0.28%) $0.936
(0.70%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally...
Stats | |
---|---|
今日成交量 | 6 059 |
平均成交量 | 28 581 |
市值 | 778 326 |
EPS | $-0.0247 ( Q3 | 2023-11-14 ) |
下一个收益日期 | ( $0 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.112 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-22 | Baker Bros. Advisors Lp | Sell | 1 941 607 | Warrants (right to buy) |
2023-11-22 | Baker Bros. Advisors Lp | Buy | 1 941 607 | Common Stock |
2023-11-22 | Baker Bros. Advisors Lp | Sell | 174 742 | Warrants (right to buy) |
2023-11-22 | Baker Bros. Advisors Lp | Buy | 174 742 | Common Stock |
2023-05-05 | Baker Bros. Advisors Lp | Buy | 0 | Common Stock |
INSIDER POWER |
---|
7.08 |
Last 91 transactions |
Buy: 8 287 527 | Sell: 2 332 728 |
Bellicum Pharmaceuticals 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Bellicum Pharmaceuticals 财务报表
Annual | 2022 |
营收: | $1.50M |
毛利润: | $1.50M (100.00 %) |
EPS: | $-0.810 |
FY | 2022 |
营收: | $1.50M |
毛利润: | $1.50M (100.00 %) |
EPS: | $-0.810 |
FY | 2021 |
营收: | $6 200.00 |
毛利润: | $6 200.00 (100.00 %) |
EPS: | $-0.000844 |
FY | 2020 |
营收: | $500.00 |
毛利润: | $500.00 (100.00 %) |
EPS: | $-0.00134 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。